A number of firms have modified their ratings and price targets on shares of HCA Healthcare (NYSE: HCA) recently:
- 11/18/2026 – HCA Healthcare had its price target raised by JPMorgan Chase & Co. from $425.00 to $475.00. They now have a “neutral” rating on the stock.
- 11/10/2026 – HCA Healthcare was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
- 11/3/2026 – HCA Healthcare had its “buy” rating reaffirmed by Truist Financial. They now have a $510.00 price target on the stock, up from $495.00.
- 11/2/2026 – HCA Healthcare had its price target raised by Wells Fargo & Company from $381.00 to $468.00. They now have an “equal weight” rating on the stock.
- 10/31/2026 – HCA Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/30/2026 – HCA Healthcare had its price target raised by Royal Bank Of Canada from $496.00 to $521.00. They now have an “outperform” rating on the stock.
- 10/29/2026 – HCA Healthcare had its price target raised by Barclays from $387.00 to $401.00. They now have an “equal weight” rating on the stock.
- 10/28/2026 – HCA Healthcare was given a new $495.00 price target by Mizuho.
- 10/28/2026 – HCA Healthcare had its price target raised by Bank of America from $450.00 to $500.00. They now have a “neutral” rating on the stock.
- 10/28/2026 – HCA Healthcare had its price target raised by TD Cowen from $460.00 to $486.00. They now have a “buy” rating on the stock.
- 10/28/2026 – HCA Healthcare had its price target raised by KeyCorp from $435.00 to $490.00. They now have an “overweight” rating on the stock.
- 10/28/2026 – HCA Healthcare had its price target raised by Robert W. Baird from $393.00 to $409.00. They now have a “neutral” rating on the stock.
- 10/12/2026 – HCA Healthcare had its price target raised by TD Cowen from $431.00 to $460.00. They now have a “buy” rating on the stock.
- 10/8/2026 – HCA Healthcare was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
- 10/7/2026 – HCA Healthcare had its price target raised by Royal Bank Of Canada from $435.00 to $496.00. They now have an “outperform” rating on the stock.
- 10/2/2026 – HCA Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 9/22/2026 – HCA Healthcare is now covered by BMO Capital Markets. They set an “outperform” rating and a $495.00 price target on the stock.
- 9/22/2026 – HCA Healthcare is now covered by BMO Capital Markets. They set an “outperform” rating and a $495.00 price target on the stock.
- 9/22/2026 – HCA Healthcare is now covered by BMO Capital Markets. They set an “outperform” rating and a $495.00 price target on the stock.
HCA Healthcare Price Performance
NYSE HCA opened at $475.84 on Thursday. The stock’s fifty day moving average price is $457.97 and its 200 day moving average price is $446.05. HCA Healthcare, Inc. has a 1 year low of $353.99 and a 1 year high of $556.52. The company has a market cap of $99.40 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 1.67 and a beta of 1.11.
HCA Healthcare (NYSE:HCA – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $7.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.65 by $0.57. The firm had revenue of $19.85 billion during the quarter, compared to analysts’ expectations of $19.33 billion. HCA Healthcare had a negative return on equity of 198.52% and a net margin of 8.61%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the business posted $6.96 earnings per share. Research analysts expect that HCA Healthcare, Inc. will post 30.14 earnings per share for the current year.
HCA Healthcare Dividend Announcement
Insider Transactions at HCA Healthcare
In related news, SVP Erica Rossitto sold 3,500 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $505.81, for a total transaction of $1,770,335.00. Following the completion of the transaction, the senior vice president owned 13,426 shares of the company’s stock, valued at $6,791,005.06. This trade represents a 20.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Schlosser sold 1,200 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $494.65, for a total transaction of $593,580.00. Following the completion of the sale, the executive vice president directly owned 1,443 shares in the company, valued at approximately $713,779.95. The trade was a 45.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,413 shares of company stock worth $18,251,464 over the last 90 days. 1.50% of the stock is currently owned by company insiders.
HCA Healthcare is a healthcare services company that operates hospitals and other care facilities. Its services include inpatient and outpatient care, emergency treatment, surgery, diagnostic services and specialized care across areas such as cancer and cardiovascular medicine. The company serves patients in the United States and the United Kingdom through its network of hospitals and outpatient facilities, including surgery centers, urgent care clinics and physician practices. Founded in 1968, HCA Healthcare is headquartered in Nashville, Tennessee.
Read More
- Five stocks we like better than HCA Healthcare
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for HCA Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare Inc and related companies with MarketBeat.com's FREE daily email newsletter.
